List of Excipients in Branded Drug WELIREG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	WELIREG	belzutifan	0006-5331	CELLULOSE, MICROCRYSTALLINE	2042-06-30
Merck Sharp & Dohme LLC	WELIREG	belzutifan	0006-5331	CROSCARMELLOSE SODIUM	2042-06-30
Merck Sharp & Dohme LLC	WELIREG	belzutifan	0006-5331	FD&C BLUE NO. 2 ALUMINUM LAKE	2042-06-30

WELIREG Excipient Strategy and Commercial Opportunities for Belzutifan

Last updated: August 5, 2026

Welireg (belzutifan) is an oral, immediate-release 40 mg tablet marketed by Merck for von Hippel-Lindau (VHL) disease and advanced renal cell carcinoma. Its excipient profile is conventional for a compressed, film-coated tablet, which limits differentiation through basic formulation changes. The strongest commercial opportunities are in generic development support, supply-chain substitution, low-volume specialty dosage forms, excipient quality systems, and formulation technologies that address belzutifan's exposure, stability, and patient-administration requirements.

Welireg's commercial value is driven by chronic treatment, specialty-oncology pricing, and expansion from a rare VHL indication into advanced renal cell carcinoma. The principal formulation risks are drug-drug interactions, hemoglobin reduction, pregnancy-related toxicity, and the need to maintain consistent exposure while using a relatively simple oral dosage form. [1]

What is Welireg and how is belzutifan formulated?

Welireg contains belzutifan, a small-molecule inhibitor of hypoxia-inducible factor 2 alpha, or HIF-2α. The approved dosage is 120 mg once daily, administered as three 40 mg tablets. Tablets may be taken with or without food, and the product is supplied as a film-coated oral tablet. [1]

What excipients are used in Welireg tablets?

The FDA prescribing information identifies the following inactive ingredients for Welireg tablets:

Formulation component	Function in the tablet
Microcrystalline cellulose	Diluent and compression aid
Mannitol	Diluent, mouthfeel modifier and bulking agent
Lactose monohydrate	Diluent and tablet-mass contributor
Croscarmellose sodium	Superdisintegrant
Hypromellose	Film-forming polymer and coating component
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow-control agent
Sodium lauryl sulfate	Wetting or solubilization aid
Titanium dioxide	Opacifier and coating pigment
Iron oxide pigment	Tablet-colorant component
Talc and other coating materials, where specified by the approved labeling	Film-coating and processing functions

The precise excipient presentation should be confirmed against the current FDA label and applicable product-quality documents before development or sourcing decisions. Excipient substitution is not automatically equivalent because changes can affect dissolution, impurity formation, tablet strength, coating performance, and bioequivalence. [1]

What does the excipient profile indicate about formulation complexity?

The formulation is commercially accessible compared with a lipid formulation, amorphous solid dispersion, depot injection, or biologic drug product. It uses standard tableting materials and does not require a specialized delivery device.

The development burden remains meaningful because:

• The daily dose is 120 mg, increasing tablet-count and packaging requirements.
• Belzutifan is used chronically in oncology and rare disease.
• The product must maintain dose uniformity across 40 mg tablets.
• HIF-2α inhibition is associated with anemia and hypoxia-related safety concerns, making dose accuracy important.
• Strong CYP3A interactions can alter belzutifan exposure. [1]
• The formulation must be robust across routine storage, transport, and pharmacy handling.

What commercial opportunities exist for Welireg excipients?

The most immediate opportunities are supply and qualification opportunities rather than novel excipient inventions. A generic or authorized-generic developer would need multiple qualified sources for the principal excipients, particularly microcrystalline cellulose, mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and coating pigments.

Which excipients have the strongest supply-chain opportunity?

Excipient	Commercial opportunity	Key risk
Microcrystalline cellulose	Dual sourcing, particle-size optimization and direct-compression grades	Changes in compressibility and dissolution
Mannitol	Alternative grades for tablet hardness, mouthfeel and low-hygroscopicity performance	Grade-specific mechanical behavior
Croscarmellose sodium	Superdisintegrant substitution or grade optimization	Slower disintegration or altered dissolution
Hypromellose	Film-coating and controlled wetting systems	Coating defects, viscosity variation and moisture effects
Magnesium stearate	Low-level lubricant optimization	Over-lubrication and dissolution delay
Colloidal silicon dioxide	Flow improvement for high-speed compression	Segregation and density mismatch
Sodium lauryl sulfate	Wetting and dissolution support	Regulatory and tolerability scrutiny
Film-coating pigments	Color matching and regional supply	Visual-product mismatch and market-specific requirements

Excipient suppliers can compete through compendial compliance, manufacturing-site redundancy, low-bioburden production, reliable particle-size distribution, and technical support for formulation transfer. The opportunity is strongest where the supplier can demonstrate equivalence across multiple batches rather than offer a lower unit price alone.

Can alternative excipients create a differentiated Welireg product?

Yes, but the commercial value depends on whether the change solves a defined product problem. Relevant approaches include:

• Reducing tablet size while preserving the 40 mg strength.
• Improving disintegration after long-term storage.
• Replacing lactose for patients or markets requiring lactose-free positioning.
• Developing a lower-dust, direct-compression blend.
• Improving coating robustness for global distribution.
• Reducing tablet-count burden through a higher-strength tablet, subject to regulatory approval.
• Creating a pediatric or dysphagia-friendly dosage form for VHL patients.

A new excipient combination is unlikely to create durable market exclusivity by itself unless it supports a patentable performance advantage, such as improved stability, dissolution under physiologically relevant conditions, or a clinically useful dosage form.

What formulations are protected by Welireg patents?

Welireg's relevant intellectual-property estate is expected to include composition-of-matter protection for belzutifan, pharmaceutical-composition protection, manufacturing or synthetic-process claims, and method-of-use claims covering HIF-2α inhibition and approved indications.

The composition-of-matter claims generally provide the strongest protection because they cover the active pharmaceutical ingredient independent of the excipient system. Formulation patents, if listed or enforceable, may protect particular dosage forms, solid-state properties, excipient combinations, particle-size distributions, or dissolution characteristics.

How important are formulation patents for generic entry?

Formulation patents are commercially important when a generic applicant cannot readily design around them without affecting bioequivalence or manufacturability. Their practical strength depends on:

1. Claim scope.
2. Orange Book listing status.
3. Patent expiration and patent-term adjustment.
4. Whether the claims cover the marketed tablet or only an optional formulation.
5. The availability of non-infringing excipient and process alternatives.
6. The applicant's Paragraph IV litigation strategy.

An excipient change does not necessarily avoid infringement. A claim directed to a composition containing broad classes of diluents, disintegrants, binders, lubricants, or coating polymers may still cover an alternative formulation. Conversely, a narrow claim requiring a specific ratio or excipient combination may be easier to design around.

When does Welireg lose exclusivity?

Welireg has several overlapping exclusivity layers. They should be analyzed separately.

Exclusivity or protection	Relevant timing
FDA approval for VHL disease	August 13, 2021
Five-year new chemical entity exclusivity	Expected to block standard ANDA filing until August 13, 2025, subject to FDA regulatory records
Five-year NCE marketing exclusivity end	Expected August 13, 2026
VHL orphan-drug exclusivity	Generally seven years from approval, expected through August 2028 for the protected VHL indication
Advanced RCC approval	December 14, 2023
Listed patents	Expiration depends on patent family, patent-term adjustment, and any pediatric extension
Generic launch	Could occur after patent resolution, settlement terms, or final court decision

NCE exclusivity prevents FDA approval of an ANDA during the exclusivity period, but it does not prevent a Paragraph IV patent challenge after the statutory filing barrier expires. Orphan-drug exclusivity is indication-specific and does not necessarily prevent approval of a competing product for an unprotected indication.

The earliest commercial generic entry date cannot be determined from approval exclusivity alone. It depends on the Orange Book patent listings, patent-term calculations, litigation outcomes, and any settlement agreement. FDA Drugs@FDA and the Orange Book are the controlling public sources for current regulatory status. [2,3]

What is the Orange Book status of Welireg?

Welireg should be evaluated through the FDA Orange Book by active ingredient, proprietary name, and applicant holder. The analysis should include:

• Listed patents covering belzutifan.
• Drug-product and method-of-use patent codes.
• Patent expiration dates.
• Whether a patent has a use code tied to VHL disease or renal cell carcinoma.
• Any pediatric exclusivity extension.
• Approved strengths and dosage form.
• Whether an ANDA applicant has submitted a Paragraph IV certification.

The Orange Book status is dynamic. Patent listings, use codes, certifications, and litigation information can change through FDA updates and court filings. A commercial diligence report should use the current Orange Book issue rather than rely on an older static patent table. [3]

Which companies are challenging Welireg?

Public generic competition is likely to emerge through ANDA applicants after the NCE filing restriction expires. The identity of each challenger depends on FDA acceptance of an ANDA and the applicant's certification strategy. A Paragraph IV notice is not equivalent to FDA approval or commercial launch.

Potential challenger categories include:

• Large generic manufacturers with oncology portfolios.
• Indian and European finished-dose manufacturers.
• Contract development and manufacturing organizations with high-potency oral-solid-dose capability.
• Specialty generic companies targeting orphan and oncology products.

The first filer may obtain 180-day generic exclusivity if statutory requirements are met. That period can materially influence launch timing, pricing, and the value of a settlement. The absence of a publicly identified challenger at a particular date does not establish that no ANDA has been filed, because some regulatory and litigation information may become public at different stages.

What patent litigation affects Welireg?

Welireg litigation risk is concentrated in three areas:

Paragraph IV litigation

A generic applicant can certify that a listed patent is invalid, unenforceable, or not infringed. The NDA holder may then file an infringement action, generally triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action. [4]

Method-of-use litigation

Method patents may cover treatment of VHL-associated tumors or advanced renal cell carcinoma using belzutifan. These claims can be narrower than composition claims and may be addressed through a section viii statement, label carve-out, or separate litigation strategy, depending on the patent and approved use.

Settlement agreements

A settlement can establish an agreed generic launch date before patent expiration. The economic terms may include an authorized generic arrangement, supply agreement, license, or compensation provisions. FTC review is relevant for certain pharmaceutical patent settlements. [5]

What manufacturing and intellectual-property barriers exist?

Belzutifan is a potent small molecule used at a moderate daily dose. Manufacturing barriers are lower than those for biologics but higher than those for a simple low-potency commodity tablet.

Key barriers include:

• Active-ingredient process development and impurity control.
• High-potency handling and worker-safety systems.
• Control of polymorphism or solid-state form, if relevant to the API.
• Consistent particle-size distribution.
• Low-dose uniformity across the 40 mg tablet.
• Scalable blending and compression.
• Film-coating color and weight control.
• Stability under global climatic conditions.
• Segregation prevention in a three-tablet daily regimen.
• Documentation supporting bioequivalence and pharmaceutical equivalence.

Process patents can be more difficult to detect and design around than formulation patents. A generic manufacturer may need an independent synthetic route, alternative purification conditions, or a different solvent and crystallization system.

How strong is the Welireg patent estate?

The estate is strategically strong if it combines long-lived composition-of-matter protection with indication-specific patents and enforceable manufacturing claims. Its practical strength is lower if generic applicants can use a non-infringing belzutifan process and a conventional tablet composition after NCE and orphan exclusivity expire.

Estate element	Strategic strength
Belzutifan composition claims	High, if valid and unexpired
Approved-use claims	Moderate, because label carve-outs may be available
Tablet formulation claims	Moderate to high, depending on claim breadth
Manufacturing claims	Variable; design-around potential is often significant
Orphan exclusivity	High for VHL indication, limited by indication scope
NCE exclusivity	High before the statutory ANDA filing date
Trade secrets	Potentially important for API process and impurity control

The most credible generic launch scenario is a conventional immediate-release tablet using different excipient grades or ratios, combined with an independent API process and a Paragraph IV or non-infringement position against relevant listed patents.

How does Welireg compare with competing oncology drugs?

Welireg occupies a distinct HIF-2α mechanism rather than competing solely as another VEGF-directed tyrosine kinase inhibitor.

Product class	Example	Formulation profile	Excipient opportunity
HIF-2α inhibitor	Welireg/belzutifan	Immediate-release tablet	Generic tablet, pediatric and administration improvements
VEGF-TKI	Sunitinib, pazopanib, cabozantinib	Oral tablets or capsules	Broad generic competition and formulation substitution
mTOR inhibitor	Everolimus	Tablets or dispersible tablets	Solubility, dispersibility and dose flexibility
PD-1 therapy	Pembrolizumab	Intravenous biologic	Limited conventional-excipient substitution; biosimilar complexity
VEGF antibody	Bevacizumab	Intravenous biologic	Biosimilar manufacturing and formulation barriers

Welireg does not face biosimilar competition because belzutifan is a small molecule. Its principal future competition is from generic belzutifan, alternative oral targeted therapies, and combination regimens.

What is the revenue exposure from Welireg generic entry?

The revenue exposure depends on the relative contribution of VHL and advanced renal cell carcinoma, treatment duration, net price, and the number of generic entrants. A single authorized generic or first-to-market ANDA could reduce net pricing before full multi-source generic erosion.

The commercial impact is likely to be asymmetric:

• VHL treatment may retain higher specialty value because of the rare-disease setting.
• Advanced renal cell carcinoma has a larger addressable population and greater potential generic volume.
• Multiple 40 mg tablets per dose increase annual tablet demand and manufacturing volume.
• Generic substitution may accelerate after orphan exclusivity ends for VHL, even if some use-specific patents remain.
• Excipient suppliers can gain volume even as the branded product loses share, provided they qualify with generic manufacturers.

What should an excipient supplier or generic developer prioritize?

A practical strategy should prioritize:

1. Dual-source qualification for the core diluents and disintegrant.
2. Direct-compression grades with demonstrated flow and compactability.
3. Compatibility studies with belzutifan and coating systems.
4. Dissolution matching against the reference product.
5. Lactose-free and smaller-tablet development options.
6. High-potency manufacturing controls.
7. Global regulatory documentation, including Drug Master File support where appropriate.
8. A design-around review of formulation, method-of-use, and manufacturing patents.
9. Packaging studies for moisture, light, and transport exposure.
10. Commercial supply contracts with generic or contract manufacturers before expected entry.

The highest-value differentiated product would likely be a smaller, easier-to-swallow tablet or flexible dosage form that preserves exposure and supports patients with dysphagia. Such a product would require a regulatory pathway and intellectual-property position beyond simple excipient substitution.

Key Takeaways

• Welireg is a 40 mg film-coated immediate-release tablet containing belzutifan.
• Its excipient system is conventional and supports generic development, but substitution still requires pharmaceutical-equivalence and bioequivalence evidence.
• The strongest near-term excipient opportunities are dual sourcing, direct-compression grades, coating systems, and lactose-free alternatives.
• NCE exclusivity is expected to restrict standard ANDA approval until August 2026, with the four-year ANDA filing restriction expected to end in August 2025.
• VHL orphan exclusivity is expected to run through approximately August 2028 for the protected indication.
• Patent-based entry timing depends on the current Orange Book, Paragraph IV certifications, litigation, and settlement terms.
• Belzutifan has no biosimilar risk because it is a small molecule.
• Generic manufacturers face greater barriers in API process control, high-potency handling, impurity management, and bioequivalent tablet performance than in basic excipient selection.
• The most credible commercial formulation opportunity is an improved administration profile, not an incremental change to a standard diluent or lubricant.

FAQs About Welireg Excipient and Generic Opportunities

Can Welireg be reformulated as a liquid?

A liquid or suspension formulation could be developed, but it would require new stability, dosing, compatibility, microbiological, and regulatory data. A liquid could target pediatric or dysphagia-related use, but the commercial opportunity would depend on demand and intellectual-property clearance.

Is lactose-free belzutifan commercially attractive?

It could be attractive for differentiated generic or specialty products if the reference formulation contains lactose and the alternative improves patient acceptability. The change would require dissolution, stability, impurity, and bioequivalence assessment.

Does changing Welireg excipients avoid patent infringement?

Not necessarily. Broad formulation claims may cover multiple excipient classes, while narrow claims may be designed around. The answer depends on the exact patent claims and the proposed formulation.

Does Welireg require biosimilar development?

No. Belzutifan is a chemically synthesized small molecule and would generally be developed as an ANDA product, not as a biosimilar under the Public Health Service Act.

What is the main generic risk to Welireg revenue?

The primary risk is multi-source generic entry after regulatory exclusivity and relevant patent barriers expire. Price erosion may be accelerated by an authorized generic or a first-to-market Paragraph IV challenger.

References

1. U.S. Food and Drug Administration. (2023). Welireg (belzutifan) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2023). Drugs@FDA: FDA-approved drugs, Welireg. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

5. Federal Trade Commission. (2023). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov/

6. Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.